Abstract:Graphical 1. Molecular profiling of tumor‐derived exosomes is crucial in facilitating the discovery of cancer‐related biomarkers. 2. Microfluidics has served as powerful components for exosomes analysis in liquid biopsy. 3. The most recent progresses in microfluidic technologies for molecular profiling of tumor‐derived exosomes, including proteins, nucleic acids, metabolites, and lipids, are summarized. Exosomes are extracellular vesicles that actively secreted by most live cells via endosome pathway. They distribute ubiquitously in body fluids and play important roles in physiological and pathological processes. Recent studies have revealed that exosomes carry cell‐specific cargoes, such as proteins and nucleic acids, which have been recognized as emerging noninvasive biomarkers in liquid biopsy. Therefore, the molecular profiling of tumor‐derived exosomes is crucial in facilitating the discovery of cancer‐related biomarkers. Recently, various techniques have been proposed for sensitive, accurate, and rapid molecular characterization of these small vesicles. To meet the growing demands for multiplexed detection, microfluidics has been integrated with diverse traditional analytical methods as powerful components for exosomes analysis. Taking advantages of their inherent merits of great sensitivity, high analysis performance and system integration, short analysis time, low cost, small volume of sample, improved potential for control, automation, and disposability, microfluidic systems have significantly improved the molecular profiling of exosomes. In this review, we summarized the most recent progresses in microfluidic technologies for molecular profiling of tumor‐derived exosomes, including proteins, nucleic acids, metabolites, lipids. Furthermore, we discussed the major challenges and offered a perspective of the microfluidic strategy‐based exosomal biomarkers discovery. We expected that the in‐depth summary of microfluidic devices–assisted analysis of exosomes will greatly facilitate the discovery of biomarkers, thereby realizing highly efficient and accurate diagnosis, and prediction of cancers. Moreover, in view of the significance of this interesting approach in exosomes‐based liquid biopsy, this review will contribute to the translation of microfluidic technology into clinical applications.

Towards microfluidic-based exosome isolation and detection for tumor therapy

Optical, Electrochemical and Electrical (nano)biosensors for Detection of Exosomes: A Comprehensive Overview

Microfluidic Approaches Toward the Isolation and Detection of Exosome Nanovesicles

Microfluidic Chips Fabrication and Integration for Tumor‐Derived Exosomes Detection

Integrated Microfluidic Platforms for Tumor-Derived Exosome Analysis

Progress in Microfluidics-Based Exosome Separation and Detection Technologies for Diagnostic Applications

Microfluidic Strategies for the Isolation and Profiling of Exosomes

Microfluidic Exosome Analysis toward Liquid Biopsy for Cancer

Current progress and prospect of microfluidic-based exosome investigation

Recent Advances of Emerging Microfluidic Chips for Exosome Mediated Cancer Diagnosis

Microfluidics‐based molecular profiling of tumor‐derived exosomes for liquid biopsy

Microfluidic-Based Exosome Analysis for Liquid Biopsy.

Exosome Separation Using Microfluidic Systems: Size‐based, Immunoaffinity‐based and Dynamic Methodologies

Microfluidic Technology for the Isolation and Analysis of Exosomes

Exosome isolation using nanostructures and microfluidic devices

Microfluidics for detection of exosomes and microRNAs in cancer: state of the art

Microfluidic Technology for Clinical Applications of Exosomes

Magnetic-Based Microfluidic Device for On-Chip Isolation and Detection of Tumor-Derived Exosomes.

Microfluidic Chips Fabrication and Integration for Tumor‐Derived Exosomes Detection (Adv. Mater. Technol. 17/2023)

Progress in the research of nanomaterial-based exosome bioanalysis and exosome-based nanomaterials tumor therapy

Microfluidic device for the analysis of MDR cancerous cell-derived exosomes’ response to nanotherapy